M42 and ArceraPartner to Advance Biopharma Localization and Next Generation Life Sciences in Abu Dhabi

Abu Dhabi, UAE – June03, 2026: M42, a global health leader powered by technology, artificial intelligence, and genomics, andArcera Life Sciences (“Arcera”), a global life sciences company focused on advancing innovative and sustainable healthcare solutions, havesigned a Memorandum of Understanding (MoU) to formalize a strategic, non-exclusive collaboration focused on advancing biopharma localization, clinical developmentand next-generation healthcare innovation in Abu Dhabi.

Aligned with the Department of Health – Abu Dhabi’s (DoH)efforts to reinforce the Emirate’s position as a global hub for life sciences innovation, the collaboration will contribute tothe development of an integrated life sciences ecosystem spanning clinical development and innovative therapeutics, addressing genetic and rare diseases with scalable treatments.

• Expansion strengthens Diaverum’s footprint in Brazil with 18 clinics and 3 vascular access centers
• Growing footprint tackles chronic kidney disease, a public health issue, with over 220,000 treatments annually
• Acquisition underpins M42’s strategy to build globally connected care platforms to improve access to high-quality care in line with data sovereignty regulations

Abu Dhabi, UAE – 23 April 2026: M42, a global health leader powered by AI, technology and genomics, and its world leading renal care business, Diaverum, today announced the completion of a strategic acquisition of four clinics in the state of São Paulo, Brazil, from the Lund Group: CDTR and CDTR Prime in Sorocaba, INDI in Itapetininga, and Lund Nefrologia in Itu. The move takes Diaverum clinics to 18 in Brazil, including three vascular access centers, affirming its long-term commitment to improving access to renal care and supporting better health outcomes in Latin America’s largest market.

• M42 and Juvenescence will collaborate in drug discovery to develop a pipeline of innovative medicines to advance the prevention and treatment of diseases of high unmet need within UAE and globally and age-related diseases
• The strategic partnership aligns with M42’s newly launched AI Life Sciences Platform
• M42’s strategic investment in Juvenescence will accelerate Juvenescence’s clinical pipeline and drug development capabilities which underscores this collaboration
• Expansion of capabilities in AI-enabled therapeutics underlines Abu Dhabi’s vision of becoming a global hub for AI-driven longevity science and next-generation drug development